Evidence map›Paper›PMID 38631707›Full record

ArticleJournal for immunotherapy of cancer2024

Germline homozygosity and allelic imbalance of HLA-I are common in esophagogastric adenocarcinoma and impair the repertoire of immunogenic peptides.

Maria Alejandra Garcia-Marquez, Martin Thelen, Eugen Bauer, Lukas Maas, Kerstin Wennhold, Jonas Lehmann, Diandra Keller, Miloš Nikolić, Julie George, Thomas Zander and 11 more

Open access · goldAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Maria Alejandra Garcia-MarquezCenter for Molecular Medicine Cologne, University of Cologne, Cologne, Germany maria.garcia-marquez@uk-koeln.de.ORCID 0000-0002-5923-5942
Martin ThelenCenter for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.ORCID 0000-0002-2785-9726
Eugen BauerInstitute of Transfusion Medicine, University of Cologne, Cologne, Germany.
Lukas MaasDepartment of Translational Genomics, University of Cologne, Cologne, Germany.
Kerstin WennholdCenter for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Jonas LehmannCenter for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Diandra KellerCenter for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Miloš NikolićDepartment of Translational Genomics, University of Cologne, Cologne, Germany.
Julie GeorgeDepartment of Translational Genomics, University of Cologne, Cologne, Germany.
Thomas ZanderDepartment I of Internal Medicine and Center for Integrated Oncology (CIO) Aachen Bonn Cologne Duesseldorf, University Hospital Cologne, Cologne, Germany.
Wolfgang SchröderDepartment of General, Visceral, Cancer and Transplantation Surgery, University of Cologne, Cologne, Germany.
Philipp MüllerCenter for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Ali M YazbeckCenter for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Christiane BrunsDepartment of General, Visceral, Cancer and Transplantation Surgery, University of Cologne, Cologne, Germany.
Roman ThomasDepartment of Translational Genomics, University of Cologne, Cologne, Germany.
Birgit GathofInstitute of Transfusion Medicine, University of Cologne, Cologne, Germany.
Alexander QuaasInstitute of Pathology, University of Cologne, Cologne, Germany.
Martin PeiferCenter for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Axel M HillmerCenter for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Michael von Bergwelt-BaildonGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Hans Anton SchlößerCenter for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
University of Cologne · DEGerman Cancer Research Center · DEDüsseldorf University Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe individual HLA-I genotype is associated with cancer, autoimmune diseases and infections. This study elucidates the role of germline homozygosity or allelic imbalance of HLA-I loci in esophago-gastric adenocarcinoma (EGA) and determines the resulting repertoires of potentially immunogenic peptides.

methodsHLA genotypes and sequences of either (1) 10 relevant tumor-associated antigens (TAAs) or (2) patient-specific mutation-associated neoantigens (MANAs) were used to predict good-affinity binders using an in silico approach for MHC-binding (www.iedb.org). Imbalanced or lost expression of HLA-I-A/B/C alleles was analyzed by transcriptome sequencing. FluoroSpot assays and TCR sequencing were used to determine peptide-specific T-cell responses.

resultsWe show that germline homozygosity of HLA-I genes is significantly enriched in EGA patients (n=80) compared with an HLA-matched reference cohort (n=7605). Whereas the overall mutational burden is similar, the repertoire of potentially immunogenic peptides derived from TAAs and MANAs was lower in homozygous patients. Promiscuity of peptides binding to different HLA-I molecules was low for most TAAs and MANAs and in silico modeling of the homozygous to a heterozygous HLA genotype revealed normalized peptide repertoires. Transcriptome sequencing showed imbalanced expression of HLA-I alleles in 75% of heterozygous patients. Out of these, 33% showed complete loss of heterozygosity, whereas 66% had altered expression of only one or two HLA-I molecules. In a FluoroSpot assay, we determined that peptide-specific T-cell responses against NY-ESO-1 are derived from multiple peptides, which often exclusively bind only one HLA-I allele.

conclusionThe high frequency of germline homozygosity in EGA patients suggests reduced cancer immunosurveillance leading to an increased cancer risk. Therapeutic targeting of allelic imbalance of HLA-I molecules should be considered in EGA.

Indexed as

AdenocarcinomaPeptidesAllelic ImbalanceAntigens, NeoplasmGerm CellsHLA AntigensHumansT-LymphocytesAntigens, NeoplasmHLA AntigensPeptidesAntigen PresentationAntigensComputational BiologyGastrointestinal NeoplasmsTumor Escape

Identifiers

PMID38631707
PMCPMC11029431
OpenAlexW4394894003

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.